Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01624454
Other study ID # SUS-CRAP
Secondary ID
Status Completed
Phase N/A
First received June 18, 2012
Last updated May 7, 2013
Start date April 2012
Est. completion date December 2012

Study information

Verified date June 2012
Source Helse Stavanger HF
Contact n/a
Is FDA regulated No
Health authority Norway: Regional Ethics Commitee
Study type Interventional

Clinical Trial Summary

Comparison between large volume and osmotic agent lavage for optimal colonoscopy bowel cleansing, randomizing adult outpatients by invitation letter


Description:

This randomized quality assurance trial aims to compare cleansing quality of two different principles of colonoscopy lavage. Large volume PEG solutions are considered safe, but cumbersome and inpalatable, while osmotic solutions are generally more acceptable, however, the risk of electrolyte disturbances or renal decompensation may increase.

The study will focus on patient experience and compliance, as well as cleansing quality, endoscopic findings and other technical parameters of the colonoscopy procedure that may be adversely affected by poor bowel cleansing. Three centers will participate, ensuring a diverse patient population. 800 patients are planned for recruitment, but an interim assessment of statistics of the primary aim parameter (bowel cleansing) will be performed to adjust the number.


Recruitment information / eligibility

Status Completed
Enrollment 380
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Pts for out-patient colonoscopy

- age 18-80

Exclusion Criteria:

- Active colitis or suspicion thereof (bloody diarrhea, fever and abdominal pain)

- Suspicion of renal insufficiency or ileus/subileus

- Previous colonic surgery

- Pregnancy

- Inability to adhere to cleansing instructions

- Inability to consent

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Other:
Laxabon
4 l PEG solution split dose cleansing
CitraFleet
Small volume osmotic bowelcleansing

Locations

Country Name City State
Norway Sørlandet sykehus Kristiansand VestAgder
Norway OUS Rikshospitalet, dept of med gastro Oslo

Sponsors (1)

Lead Sponsor Collaborator
Helse Stavanger HF

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bowel cleansing quality 1 Day No
Secondary Colonoscopy findings 1 Day No